Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logothetis

Showing results (741-750 of 1,104) with videos related to

Pageof 111
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin TargetingClaudia Paindelli, Stefano Casarin, Feng Wang, et al.
ACS Nano|December 14, 2017
Exploring the Nanotoxicology of MoS<sub>2</sub>: A Study on the Interaction of MoS<sub>2</sub> Nanoflakes and K<sup>+</sup> ChannelsZonglin Gu, Leigh D Plant, Xuan-Yu Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis|August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillanceXiang Shu, Yuanqing Ye, Jian Gu, et al.
Molecular Pain|August 13, 2009
Subtype-specific regulation of P2X3 and P2X2/3 receptors by phosphoinositides in peripheral nociceptorsGary Mo, Louis-Philippe Bernier, Qi Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancerArlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2012
PIP2 controls voltage-sensor movement and pore opening of Kv channels through the S4-S5 linkerAldo A Rodriguez-Menchaca, Scott K Adney, Qiong-Yao Tang, et al.
The Prostate|July 4, 2012
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancersEleni Efstathiou, Maria Karlou, Sijin Wen, et al.
Anticancer Research|November 3, 2004
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancerKarim Fizazi, Charles R Sikes, Jeri Kim, et al.
Pageof 111

Showing results (741-750 of 1,104) with videos related to

Sort By:
Pageof 111
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 29, 2021
Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<b>β</b>1 Integrin TargetingClaudia Paindelli, Stefano Casarin, Feng Wang, et al.
ACS Nano|December 14, 2017
Exploring the Nanotoxicology of MoS<sub>2</sub>: A Study on the Interaction of MoS<sub>2</sub> Nanoflakes and K<sup>+</sup> ChannelsZonglin Gu, Leigh D Plant, Xuan-Yu Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Carcinogenesis|August 13, 2016
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillanceXiang Shu, Yuanqing Ye, Jian Gu, et al.
Molecular Pain|August 13, 2009
Subtype-specific regulation of P2X3 and P2X2/3 receptors by phosphoinositides in peripheral nociceptorsGary Mo, Louis-Philippe Bernier, Qi Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancerArlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2012
PIP2 controls voltage-sensor movement and pore opening of Kv channels through the S4-S5 linkerAldo A Rodriguez-Menchaca, Scott K Adney, Qiong-Yao Tang, et al.
The Prostate|July 4, 2012
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancersEleni Efstathiou, Maria Karlou, Sijin Wen, et al.
Anticancer Research|November 3, 2004
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancerKarim Fizazi, Charles R Sikes, Jeri Kim, et al.
Pageof 111